Lates News

According to a report released by Wanlian Securities on April 6th, "buy" rating was given to Wanmei Biology (603983.SH). The reasons for the rating mainly include: 1) rapid growth in revenue, short-term pressure on profits; 2) continuous iteration of products, rapid growth in revenue in eye care and skincare businesses; 3) year-on-year increase in gross profit margin, higher growth in sales and management expense ratio. (Daily Economic News)